{"id":"disitamab-vedotin-tislelizumab-oxaliplatin-capecitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Disitamab vedotin is an anti-HER2 antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cells. Tislelizumab is a PD-1 inhibitor that relieves immune checkpoint suppression to enhance anti-tumor immunity. Oxaliplatin and capecitabine provide additional chemotherapy-mediated cytotoxicity and synergistic anti-tumor effects in the combination regimen.","oneSentence":"This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:38.128Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HER2-positive gastric or gastroesophageal junction cancer (phase 3)"}]},"trialDetails":[{"nctId":"NCT07315750","phase":"PHASE3","title":"A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2026-01-01","conditions":"Gastric Carcinoma","enrollment":555},{"nctId":"NCT06944496","phase":"PHASE3","title":"A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2025-05-15","conditions":"Gastric Carcinoma","enrollment":616}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","genericName":"Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine","companyName":"RemeGen Co., Ltd.","companyId":"remegen-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This combination therapy targets HER2-positive gastric cancer through antibody-drug conjugate-mediated tumor cell killing, immune checkpoint inhibition, and chemotherapy-induced DNA damage. Used for HER2-positive gastric or gastroesophageal junction cancer (phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}